-
Mercados
-
Acções
Sustainable finance2025 Euronext ESG Trends ReportRead moreA data-driven snapshot of how Euronext-listed companies are advancing their Environmental, Social and Governance (ESG) practices.
-
índices
A milestone in a decade of transformationEuronext joins the CAC 40®Read moreAs of 22 September 2025, Euronext has officially joined the CAC 40®, France’s flagship blue-chip index.
-
ETFs
The European market place for ETFsEuronext ETF EuropeRead moreInvestors benefit from a centralised market place that will not only bring transparency but also better pricing due to the grouping of liquidity.
- Fundos
-
Obrigações
European Defence BondsGroupe BPCE lists the first bondRead moreFirst financial institution in Europe to issue a bond dedicated to the defence sector
- Warrants & Certificados
-
Derivados
Where European Government Bonds Meet the FutureFixed Income derivativesRead moreTrade mini bond futures on main European government bonds
-
Matérias-Primas
- Vista global
- Quotes snapshot
- Power Derivatives
- Milling Wheat derivatives
- Corn derivatives
- Spread contracts
- Rapeseed derivatives
- Durum Wheat derivatives
- Salmon derivatives
- Entrega e liquidação
- Especificações e disposições
- Commitments of Traders (CoT) report
- Commodity brokers
Building a sustainable and liquid power derivatives market.Euronext Nord Pool Power FuturesRead moreEuronext and Nord Pool, the European power exchange, announced the launch of a dedicated Nordic and Baltic power futures market.
-
Recursos
Designed to help students navigate the complexities of financial marketsEuronext Trading gameRead moreJoin the Euronext Trading Game and step into capital markets. Learn from today’s leaders, explore sustainable opportunities, and trade with confidence.
Company press releases
| Released | Company | Title | Industry | Topic |
|---|---|---|---|---|
| 14 Aug 2024 07:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces Issuance of Key Patent Covering Individualized Neoantigen Based Vaccines | 20103010 Biotechnology | Non-regulatory press releases |
| 01 Aug 2024 08:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics – invitation to Q2 2024 financial results presentation | 20103010 Biotechnology | Non-regulatory press releases |
| 01 Jul 2024 20:20 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Grant of share options | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 20 Jun 2024 07:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at FOCIS 2024 Meeting | 20103010 Biotechnology | Non-regulatory press releases |
| 11 Jun 2024 07:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces mRNA-LNP Cancer Vaccine Demonstrates Superior Efficacy | 20103010 Biotechnology | Non-regulatory press releases |
| 24 May 2024 17:15 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Grant of share options | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 16 May 2024 11:46 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics ASA - Minutes of Annual General Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 14 May 2024 07:15 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer | 20103010 Biotechnology | Non-regulatory press releases |
| 14 May 2024 07:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Quarterly report Q1 2024 | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
| 07 May 2024 07:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics – invitation to Q1 2024 financial results presentation | 20103010 Biotechnology | Non-regulatory press releases |
| 25 Apr 2024 07:30 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics ASA - Notice of Annual General Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 19 Apr 2024 07:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer | 20103010 Biotechnology | Non-regulatory press releases |
| 19 Apr 2024 06:30 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Annual Report 2023 | 20103010 Biotechnology | Annual financial and audit Reports |
| 26 Mar 2024 15:30 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 21 Mar 2024 19:38 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 21 Mar 2024 07:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer | 20103010 Biotechnology | Non-regulatory press releases |
| 19 Mar 2024 07:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces Advances in the Inverse Vaccine Platform With the Potential to Treat Autoimmune Diseases | 20103010 Biotechnology | Non-regulatory press releases |
| 13 Mar 2024 14:57 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 08 Mar 2024 16:16 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 08 Mar 2024 13:31 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 04 Mar 2024 13:11 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 29 Feb 2024 16:27 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 28 Feb 2024 07:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Quarterly report Q4 2023 | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
| 22 Feb 2024 07:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics – invitation to Q4 2023 financial results presentation | 20103010 Biotechnology | Non-regulatory press releases |
| 19 Dec 2023 07:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference | 20103010 Biotechnology | Non-regulatory press releases |
| 18 Dec 2023 21:19 CET |
NYKODE THERAPEUTICS ASA | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 14 Dec 2023 07:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics Announces Expansion of Oncology Pipeline Aiming to Reduce the Burden of Colorectal Cancer | 20103010 Biotechnology | Non-regulatory press releases |
| 07 Dec 2023 18:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Share capital increase from exercise of warrants | 20103010 Biotechnology | Total number of voting rights and capital |
| 28 Nov 2023 10:49 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Share capital increase from exercise of warrants | 20103010 Biotechnology | Total number of voting rights and capital |
| 24 Nov 2023 18:20 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics – Primary insider transaction | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 15 Nov 2023 07:00 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Quarterly report Q3 2023 | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
| 10 Nov 2023 17:13 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Share capital increase from exercise of warrants | 20103010 Biotechnology | Total number of voting rights and capital |
| 09 Nov 2023 08:30 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics – invitation to Q3 2023 financial results presentation | 20103010 Biotechnology | Non-regulatory press releases |
| 07 Nov 2023 08:30 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics to Present at Jefferies Healthcare Conference | 20103010 Biotechnology | Non-regulatory press releases |
| 31 Oct 2023 15:30 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 31 Oct 2023 14:41 CET |
NYKODE THERAPEUTICS ASA | Disclosure of shareholding | 20103010 Biotechnology | Major shareholding notifications |
| 31 Oct 2023 09:16 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics ASA – New Share Capital Registered | 20103010 Biotechnology | Total number of voting rights and capital |
| 30 Oct 2023 23:29 CET |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics ASA – Subsequent Offering Cancelled | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 27 Oct 2023 16:15 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 25 Oct 2023 17:22 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of trade by closely associated party of a primary Insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 25 Oct 2023 15:32 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Mandatory notification of trade by closely associated party of a primary Insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 25 Oct 2023 14:33 CEST |
NYKODE THERAPEUTICS ASA | Disclosure of shareholding | 20103010 Biotechnology | Major shareholding notifications |
| 25 Oct 2023 08:15 CEST |
NYKODE THERAPEUTICS ASA | Disclosure of shareholding | 20103010 Biotechnology | Major shareholding notifications |
| 25 Oct 2023 02:05 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics ASA – Share Lending by Closely Associated Parties of a Primary Insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 25 Oct 2023 01:54 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics ASA – Key Information Regarding Subsequent Offering | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 25 Oct 2023 01:50 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics ASA - Private Placement Completed | 20103010 Biotechnology | Inside information |
| 24 Oct 2023 16:30 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics ASA - Contemplated Private Placement | 20103010 Biotechnology | Inside information |
| 23 Oct 2023 20:58 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics - Update on process with the Norwegian Tax Authorities | 20103010 Biotechnology | Non-regulatory press releases |
| 12 Oct 2023 16:00 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics – presentation from the mRNA Cancer Vaccines Summit 2023 in Boston | 20103010 Biotechnology | Non-regulatory press releases |
| 09 Oct 2023 06:45 CEST |
NYKODE THERAPEUTICS ASA | Nykode Therapeutics to Present at the mRNA Cancer Vaccines Summit 2023 in Boston | 20103010 Biotechnology | Non-regulatory press releases |